35. Events after balance sheet date

35. Events after balance sheet date

On 17 January 2017 we announced the appointment of Dr. Walid Abi-Saab as Chief Medical Officer and member of the executive committee, beginning on 1 March 2017.

On 20 January 2017 the board of directors conditionally issued 150,000 warrants within the framework of the authorized capital, for the benefit of Dr. Abi-Saab (“Warrant Plan 2016 (B)”). The issuance of the warrants is subject to acceptance by Dr. Abi-Saab. These warrants have a term of eight years and an exercise price of €62.50.

On 1 February 2017 we announced the dosing of the first patient with CF Class III (F508del and a gating mutation like G551D) with our novel CF corrector GLPG2222 as an add-on to Kalydeco® in a Phase 2a study. We also announced the opening of an Investigational New Drug file with the U.S. Food & Drug Administration for GLPG2222, which triggered a $10 million milestone payment from AbbVie to Galapagos.

On 10 March 2017 we announced the initiation of two additional Phase 2 studies with filgotinib: one in small bowel Crohn’s disease, and one in fistulizing Crohn’s disease.

On 22 March 2017 we announced the initiation of a Phase 1 trial with GLPG3067, triggering a $7.5 milion milestone payment from our collaboration partner AbbVie.

Our consolidated financial statements were approved by the board of directors and authorized for publication, on 21 March 2017. They were signed on behalf of the board of directors by:

Onno van de Stolpe
Managing Director and CEO
21 March 2017